Agency: Department of Defense | Branch: Army | Program: STTR | Phase: Phase I | Award Amount: 100.00K | Year: 2010
High efficiency, low pollution, and long lifetime make hydrogen-powered fuel cells desirable for portable power generation by the Army. However, it is impractical to transport hydrogen to where it is needed. Instead, reforming a transportable liquid fuel such as JP-8 or diesel fuel can produce the hydrogen for the fuel cell. Noble metal catalysts can speed this reforming, but they are expensive and easily deactivated by formation of carbon deposits, and by fuel contaminants such as sulfur. NanoScale Corporation and Kansas State University propose to develop catalysts and catalytic systems that can efficiently convert logistic fuels to hydrogen without suffering deactivation from coking or sulfur poisoning. Research efforts will target ways to reduce the costs of fuel reforming systems, either by developing new catalysts to replace expensive noble metal catalysts or developing ways to reduce the required metal loading. This project will address these objectives by using bimetallic nanoparticles based on platinum and nickel to catalyze the partial oxidation of logistic fuels. NanoScale has great experience in synthesis, characterization, and manufacture of metal nanoparticles and nanocrystalline metal oxides, while Prof. Keith Hohn is an expert in catalytic systems for reforming hydrocarbons into hydrogen.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 1.00M | Year: 2010
Early diagnosis and treatment of cancer greatly improve the likelihood of long-term survival and health. In Phase I, NanoScale Corporation and its partners at Kansas State University developed functionalized cancer-seeking "stealth" Fe/Fe3O4 core/shell nanoparticles, and demonstrated their feasibility for diagnosis of cancer by optical imaging. In Phase II, the NanoScale/KSU team will optimize the nanoparticles for diagnosis of breast cancer by fluorescence optical imaging, giving the surgeon an immediate technique for identifying the tumor margin. A maximum Tolerated Dose study, including a Repeat Dose phase, will evaluate toxicity in rats. An Ames test will evaluate mutagenic potential. Ex vivo studies with excised breast tumor specimens will determine the ability of the functionalized nanoparticles to improve margin identification. A Clinical Study Report will be prepared, and discussed with FDA personnel in a pre-IND meeting. Strategic alliances with recognized diagnostic/imaging companies will be established. NanoScale has extensive experience in synthesis, manufacture, and characterization of metal and metal oxide nanoparticles. Professors Stefan Bossmann and Deryl Troyer are internationally recognized for their accomplishments in synthesizing and evaluating anti-cancer compounds. Dr. Mark Cohen, surgical oncologist, is an expert in evaluating novel targeted therapies. Dr. Scott Weir has great experience in drug development and registration.
Nanoscale Corporation Inc and Kansas State University | Date: 2010-08-31
The present invention provides multifunctional nanoplatforms for assessing the activity of a protease in vivo or in vitro, along with methods of imaging and detecting the presence of cancerous or precancerous tissues, and the therapeutic treatment thereof, including monitoring of treatment. The diagnostic nanoplatforms comprise nanoparticles and are linked to each other or other particles via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected using various sensors, and the diagnostic results can be correlated with cancer prognosis. Individual unlinked nanoplatforms are also adaptable for therapeutic hyperthermia treatment of the cancerous tissue.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 200.00K | Year: 2011
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in urine and blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in urine and blood via simple fluorescence measurements. The severing from the nanoparticle stops the efficientfluorescence quenching of the organic luminophore by the nanoparticle, thus allowing the detection of the protease activity. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/ invasion. The focus will be on pancreatic cancer, and the studies will be done on urine and blood from 30 patients and 12 healthy individuals. Measuring twelve proteases in total that are linked to pancreatic cancer progression will allow us to obtain statistically significant measurements within 1 hour.
Nanoscale Corporation Inc | Date: 2012-10-17
Apparatus and methods for reducing or eliminating undesirable air-borne substances, such as odors, bacteria, viruses, fungi, and toxins, are provided. A filter containing nanocrystalline metal oxide or metal hydroxide particles may be installed within an air handling apparatus such as an existing HVAC unit located within a building, and particularly within a home, or a portable air processor or purifier. The air handling apparatus comprises a blower which pulls air containing various undesirable substances from within the enclosed environment and directs it through a filtering device containing the nanocrystalline particles. The undesirable substances are sorbed by the nanocrystalline particles thereby creating a deodorized stream of air that may then be directed back into various portions of the enclosed environment or vented to the atmosphere.